These data suggest that both the expression of gene variants of signaling pathways (protein kinases C, G, and A, RhoA, PI3/Akt, and Wnt) which control BBB function in patients and investigation of the disrupted pathways in autism may yield druggable targets [160]. This evidence concerns the gene AKT1 and autism.